https://www.theedgemarkets.com/article/pfizer-files-covid19-vaccine-application-us-fda

Pfizer files Covid-19 vaccine application to US FDA

https://www.theedgemarkets.com/article/pfizer-files-covid19-vaccine-application-us-fda

Pharmaniaga aims to produce halal vaccine

https://webcache.googleusercontent.com/search?q=cache:0LM1JsCfVnsJ:https://www.thestar.com.my/business/business-news/2020/11/21/pharmaniaga-aims-to-produce-halal-vaccine+&cd=4&hl=en&ct=clnk&gl=my

Furthermore those middleman and ancillary companies are most probably not public listed. So really not my concern at all. My focus is on Kanger alone.

@Kanna111 They will deal with Ministry of Health (MOH) via Zuellig Pharma. Go this website you will see so many registered products whereby Zuellig Pharma acts as the product registration holder. Click search by "Holder Name".

https://www.npra.gov.my/index.php/en/consumers/information/products-search.html

K-Star will be the sales agent of Covid-19 vaccines for private clinics in Malaysia while Zuellig Pharma has vast experience in distributing vaccines to MOH/KKM facilities/hospitals as well as private hospitals all around Malaysia.

GI Healthcare has no special role other than to sponsor the vaccines for emergency use of frontliners/ vulnerable groups (to fulfill their corporate social responsibility).

@Noobie 123 What you said is most likely the case. Pfizer vaccine is a good example. I would't be surprised that a large portion of all the other western vaccines ie Moderna, Astrazeneca/Oxford, Johnson & Johnson and Novavax vaccine have mostly probably also been presold to rich developed countries.


Pfizer vaccine: Over 80% of doses already sold to world’s richest countries

https://www.independent.co.uk/news/health/covid-pfizer-vaccine-doses-latest-uk-supplies-b1721162.html

Please see the Astroawani news in this link which explains clearly the choice of vaccine for Malaysia : https://www.facebook.com/astroawani/videos/1298653727225272/

I believe that the vaccine from China (Sinopharm is currently ahead of Sinovac and Cansino in phase III trial at the moment) will take the largest slice of the cake of covid-19 vaccination in Malaysia. Pfizer vaccine (which requires -70C storage), Moderna vaccine (which requires -20C storage) and Sputnik V Vaccine (which requires -18C storage) are all out of the question. Johnson & Johnson and Astrazeneca/Oxford vaccine are pretty unlikely as well as phase III trials have been halted before due to major side effects (The Ministry of Health Malaysia is always pretty cautious on this and would rather not take any risks. Hence this most probably also rules out Sputnik V vaccine and Cansino vaccine which are also based on the same platform/technology as Johnson & Johnson and Astrazeneca/Oxford vaccine ie Adenovirus vector vaccine). Novavax vaccine (based on protein subunit platform) is possible but unfortunately its phase III trial is quite behind China vaccines (Its phase 3 interim data only expected first quarter of 2021. Full data will only be available later in 2021).

@18KHarmoni I am a pharmacist by profession and no i am not a member of MPCN.

@angelo To be honest , I have never ever heard of the Taiwanese company linked to metronic in my entire life (I am a health professional btw). Furthermore, the vaccine has only just begun phase I clinical trial.

@SinGor Sorry, I have to correct you there. It is not Sinovac, it is Sinopharm which is linked to Kanger. Both are based on inactivated vaccine platform. Go go Kanger !!!!

Published: 3:21pm, 20 Nov, 2020

The news comes as state-owned China National Biotec Group (CNBG) on FRIDAY began reviewing the PHASE 3 TRIAL DATA for its TWO INACTIVATED VACCINES, Yang Xiaoming, chairman of parent company SINOPHARM, said.

Speaking on the sidelines of the conference, SINOPHARM’s Yang said CNBG was expecting to review the data from the phase 3 trials of its Covid-19 vaccines on Friday.

“I must return to Beijing today for an urgent matter … we will have a partial review of the data of our vaccines,” Yang, chairman of SINOPHARM, said.

“We had part of the data reviewed recently and I am going back today to handle it. I am not at liberty to disclose details, but the RESULTS ARE GOOD,” he said.

The inactivated vaccines developed by the state-owned CNBG have been undergoing final stage trials in 10 countries outside China, the first of which began in June.

More than 50,000 people had received the first of a two-dose regimen, with 48,000 of those going on to have the second, Yang said.

Zhong Nanshan, one of China’s top respiratory disease experts, said at the conference attended by Yang that he was CONFIDENT the Chinese vaccines WOULD HAVE GOOD EFFICACY RATES.

On the success of the foreign vaccines, he said: “Pfizer and Moderna have already published their results and the whole world is excited about it, but I am not impressed.”

“I don’t care if the efficacy reaches such a high level, like 95 per cent,” Zhong said. “[Our] vaccine is EFFECTIVE and it can be produced on a LARGE SCALE, and that’s the biggest guarantee.

“I suggest [we] keep an open mind about all types of vaccines as we don’t know how protective the [mRNA] vaccine will be, how long the protection will last and how significant the adverse effects will be in the long run,” he said, referring to the technology used by Pfizer-BioNTech and Moderna.

“With the exception of emergency use authorisation, a vaccine needs at least six months to determine its [true efficacy],” Zhong said.

Nearly 1 million Chinese have been given the inactivated vaccines under the government’s emergency use scheme. Before then, in March, several executives of SINOPHARM and its subsidiaries, including Yang, were injected with the vaccine.

Yang said tests had shown he still had antibodies in his system six months later.

https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3

Published: 3:21pm, 20 Nov, 2020

The news comes as state-owned China National Biotec Group (CNBG) on FRIDAY began reviewing the PHASE 3 TRIAL DATA for its TWO INACTIVATED VACCINES, Yang Xiaoming, chairman of parent company SINOPHARM, said.

Speaking on the sidelines of the conference, SINOPHARM’s Yang said CNBG was expecting to review the data from the phase 3 trials of its Covid-19 vaccines on Friday.

“I must return to Beijing today for an urgent matter … we will have a partial review of the data of our vaccines,” Yang, chairman of SINOPHARM, said.

“We had part of the data reviewed recently and I am going back today to handle it. I am not at liberty to disclose details, but the RESULTS ARE GOOD,” he said.

The inactivated vaccines developed by the state-owned CNBG have been undergoing final stage trials in 10 countries outside China, the first of which began in June.

More than 50,000 people had received the first of a two-dose regimen, with 48,000 of those going on to have the second, Yang said.

Zhong Nanshan, one of China’s top respiratory disease experts, said at the conference attended by Yang that he was CONFIDENT the Chinese vaccines WOULD HAVE GOOD EFFICACY RATES.

On the success of the foreign vaccines, he said: “Pfizer and Moderna have already published their results and the whole world is excited about it, but I am not impressed.”

“I don’t care if the efficacy reaches such a high level, like 95 per cent,” Zhong said. “[Our] vaccine is EFFECTIVE and it can be produced on a LARGE SCALE, and that’s the biggest guarantee.

“I suggest [we] keep an open mind about all types of vaccines as we don’t know how protective the [mRNA] vaccine will be, how long the protection will last and how significant the adverse effects will be in the long run,” he said, referring to the technology used by Pfizer-BioNTech and Moderna.

“With the exception of emergency use authorisation, a vaccine needs at least six months to determine its [true efficacy],” Zhong said.

Nearly 1 million Chinese have been given the inactivated vaccines under the government’s emergency use scheme. Before then, in March, several executives of SINOPHARM and its subsidiaries, including Yang, were injected with the vaccine.

Yang said tests had shown he still had antibodies in his system six months later.

https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3

Published: 3:21pm, 20 Nov, 2020

The news comes as state-owned China National Biotec Group (CNBG) on FRIDAY began reviewing the PHASE 3 TRIAL DATA for its TWO INACTIVATED VACCINES, Yang Xiaoming, chairman of parent company SINOPHARM, said.

Speaking on the sidelines of the conference, SINOPHARM’s Yang said CNBG was expecting to review the data from the phase 3 trials of its Covid-19 vaccines on Friday.

“I must return to Beijing today for an urgent matter … we will have a partial review of the data of our vaccines,” Yang, chairman of SINOPHARM, said.

“We had part of the data reviewed recently and I am going back today to handle it. I am not at liberty to disclose details, but the RESULTS ARE GOOD,” he said.

The inactivated vaccines developed by the state-owned CNBG have been undergoing final stage trials in 10 countries outside China, the first of which began in June.

More than 50,000 people had received the first of a two-dose regimen, with 48,000 of those going on to have the second, Yang said.

Zhong Nanshan, one of China’s top respiratory disease experts, said at the conference attended by Yang that he was CONFIDENT the Chinese vaccines WOULD HAVE GOOD EFFICACY RATES.

On the success of the foreign vaccines, he said: “Pfizer and Moderna have already published their results and the whole world is excited about it, but I am not impressed.”

“I don’t care if the efficacy reaches such a high level, like 95 per cent,” Zhong said. “[Our] vaccine is EFFECTIVE and it can be produced on a LARGE SCALE, and that’s the biggest guarantee.

“I suggest [we] keep an open mind about all types of vaccines as we don’t know how protective the [mRNA] vaccine will be, how long the protection will last and how significant the adverse effects will be in the long run,” he said, referring to the technology used by Pfizer-BioNTech and Moderna.

“With the exception of emergency use authorisation, a vaccine needs at least six months to determine its [true efficacy],” Zhong said.

Nearly 1 million Chinese have been given the inactivated vaccines under the government’s emergency use scheme. Before then, in March, several executives of SINOPHARM and its subsidiaries, including Yang, were injected with the vaccine.

Yang said tests had shown he still had antibodies in his system six months later.

https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3

@KLBullTrader Okay whatever go and continue buying mahsing stocks LOL So delusional....

How did you guys know about the vaccine even before news was published? Someone shared insider info here??

Metronic aims RM180 million profit from Covid-19 vaccine

KUALA LUMPUR: Metronic Global Bhd (MGB) through its subsidiary Metronic Medicare Sdn Bhd (MMSB), has inked a memorandum of agreement (MoA) with Medigen Vaccine Biologics Corporation (MVC), to distribute Covid-19 vaccine in Malaysia and potentially other countries.

https://www.nst.com.my/business/2020/11/642928/metronic-aims-rm180-million-profit-covid-19-vaccine

@MadCow75 Yes, simple as that. So pathetic this 18KHarmoni...

ZZZZZ....This company is NOT a con counter nor is it a goreng counter... Plsss.....

Bamboo or not, this counter has great potential...

@MadCow75 This 18KHarmoni has ulterior motives if you know what i mean. If you noticed earlier he kept on saying he wants to buy in at 10C so he kept on queueing at that 10c but tak dapat. Now he is suddenly so "concerned" about other ppl. This fella doesnt care about other ppls money. He only cares about himself. LOL

@MadCow75 Exactly. Its all public knowledge from published news articles and bursa announcements unless you are "katak di bawah tempurung".

@18KHarmoni You are insulting the intelligence of other people who are able to do their own research and make their own judement and informed decisions. Have a little faith. Whatever i share is from published sources. No fake news here. No speculations. You really should take a chill pill.

Okay Que Sera, Sera, Whatever Will Be, Will Be....

@18KHarmoni and whos to say i did not share any info regarding bamboo? i did share a couple of info regarding bamboo. Not sure you even bother to read.

@18KHarmoni Nobody is stopping you from sharing info about bamboo flooring. Rather than keep barking, why don't you start sharing some info?? You should "Talk The Talk, Walk The Walk"

lol this18KHarmoni joker keeps on appearing out of nowhere. Funny fella.

Sinopharm Vaccine from China is guaranteed to be affordable to developing countries in the ASEAN region.

------------------
Ditanya sama sekiranya vaksin yang dihasilkan di China lebih murah daripada vaksin yang dihasilkan di Amerika Syarikat dan Eropah, Hong berkata perkara itu sudah dinyatakan oleh pemimpin China berulang kali.

"Dalam Sidang Kemuncak ASEAN baru-baru ini pemimpin China menegaskan ASEAN akan diutamakan setelah vaksin China berjaya dihasilkan serta akan disenaraikan sebagai produk awam yang MAMPU DIBAYAR oleh semua negara membangun.

"Walaupun beberapa syarikat farmaseutikal telah mengumumkan harganya, namun itu bukanlah matlamat kerana ini merupakan cabaran global jadi ia memerlukan satu bentuk penyelarasan.

"Jadi harganya MUNGKIN LEBIH MURAH berbanding negara-negara barat dan paling penting tidak kira berapa harganya, dari mana datangnya vaksin ia merupakan satu berita gembira kepada seluruh umat manusia sekiranya berjaya dihasilkan dengan berkesan," ujar beliau.

https://www.astroawani.com/berita-dunia/lima-calon-vaksin-covid19-china-masuk-ujian-fasa-akhir-mungkin-lebih-murah-268987

KKM must have posted the information in a rush.

You can refer to this link from World Health Organization below regarding the vaccine platform/ technology used for Novavax Vaccine

https://www.who.int/docs/default-source/coronaviruse/risk-comms-updates/update37-vaccine-development.pdf?sfvrsn=2581e994_6

@Noobie123 Unfortunately i have spotted a mistake from KKM Facebook source. The correct info is as follows which are in capital letters. I have also added the name/company associated with the vaccine platforms listed below :

Terdapat 10 vaksin COVID-19 yang sedang diteliti oleh KKM yang telah memasuki FASA III kajian klinikal iaitu

4 vaksin dari jenis Viral Vector Vaccine - JOHNSON & JOHSON, ASTRAZENECA/OXFORD, CANSINO, SPUTNIK V

3 vaksin dari jenis Inactivated Virus Vaccine - 2 VACCINES FROM SINOPHARM , 1 VACCINE FROM SINOVAC

2 vaksin dari jenis RNA Based Vaccine - PFIZER, MODERNA

1 vaksin dari jenis PROTEIN SUBUNIT VACCINE - NOVAVAX

KKM akan menganalisis untuk melihat aspek keselamatan serta keberkesanan vaksin tersebut sebelum diluluskan penggunaannya.

PLEASE NOTE :
1. PROTEIN SUBUNIT VACCINE IS NOT THE SAME AS VIRUS LIKE PARTICLE VACCINE.
2. VIRUS LKE PARTICLE VACCINE IS THE SAME AS NANOPARTICLE VACCINE (BOTH ARE SYNONYMOUS)

Tuberculosis and polio vaccines may offer temporary protection against SARS-CoV-2

https://www.news-medical.net/news/20200614/Tuberculosis-and-polio-vaccines-may-offer-temporary-protection-against-SARS-CoV-2.aspx

Spain authorises Phase III trial of Johnson & Johnson COVID-19 vaccine

https://www.thestar.com.my/news/world/2020/11/18/spain-authorises-phase-iii-trial-of-johnson--johnson-covid-19-vaccine

Spain authorises Phase III trial of Johnson & Johnson COVID-19 vaccine

https://www.thestar.com.my/news/world/2020/11/18/spain-authorises-phase-iii-trial-of-johnson--johnson-covid-19-vaccine

@purple_rain

You can refer here for more info on the agreement between Sinopharm and Kanger.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=107445&name=EA_GA_ATTACHMENTS

https://www.theedgemarkets.com/article/kanger-collaborate-sinopharm-distribution-covid19-vaccine%C2%A0

https://www.theedgemarkets.com/article/kanger-ropes-more-collaborators-help-distribute-covid19-vaccines

https://www.nst.com.my/business/2020/10/632004/kanger-boosted-malaysia-chinas-priority-vaccine-recipient-list

https://www.nst.com.my/business/2020/09/628322/kanger-sinopharm-inks-agreement-covid-19-vaccine-distribution-malaysia

@purple_rain You can interpret it however you want but it is clear from that article that their role is to sponsor 10,000 doses of the vaccine for emergency use of Malaysian frontliners, especially medical and police personnel ONLY. NOT to supply or distribute the vaccines.

@purple_rain

The 10,000 doses of Sinopharm Vaccine to be sponsored is by Sinopharm and GI Healthcare Resources Sdn Bhd is merely to fulfill their corporate social responsibility (CSR) to donate 10,000 doses of Sinopharm Vaccine for emergency use of frontliners only, NOT FOR GENERAL PUBLIC. They will not be distributing the vaccines.

Please note that Emergency use is NOT the same as full approval. It is merely a form of conditional authorization of the vaccine to be used by specific targeted groups such as frontliners and vulnerable groups ONLY (and NOT FOR GENERAL PUBLIC). Emergency use authorization is just based on interim clinical trial results (pending the completion of phase III clinical trial). Once the phase III clinical trial of Sinopharm Vaccine is completed very soon, the complete clinical data of the vaccine can then be submitted to the Ministry of Health (MOH) for evaluation and approval. Upon receiving FULL APPROVAL of the vaccine by Ministry of Health (MOH), the vaccine can then be used for the GENERAL PUBLIC.

Kanger in collaboration with Zuellig Pharma and Kstar will be the ones distributing the vaccines to private and government hospitals and clinics.

BREAKING NEWS !!

-------------------------------------

Coronavirus: China’s CNBG set to review Covid-19 vaccine phase 3 trial results
• Partial review of data expected to take place on Friday afternoon, chairman of China National Biotec Group’s parent company Sinopharm says
• Chinese epidemiologist Zhong Nanshan says he is ‘not impressed’ with the vaccine efficacy results achieved by Pfizer-BioNTech and Moderna, two of which are American firms



China National Biotec Group (CNBG) is expected to review the data from the phase 3 trials of its Covid-19 vaccines on Friday afternoon, according to the boss of its parent company.

“I must return to Beijing this afternoon for an urgent matter … we will have a partial review of the data of our vaccines,” Yang Xiaoming, chairman of Sinopharm, told about 4,000 people at an industry conference in the south China city of Zhuhai.

The inactivated vaccines developed by the state-owned CNBG entered final stage trials in 10 countries outside China in June.

Yang said the trials involved 50,000 people of 125 nationalities, and that the data already collected about the safety of the products was “very good”.

The news from CNBG comes after German firm BioNTech and American company Pfizer said on Wednesday that their jointly developed vaccine had achieved 95 per cent efficacy in the final analysis of its global clinical trial.

Two days earlier, American firm Moderna said its vaccine was 94.5 per cent effective in preventing Covid-19 based on interim data from a late-stage clinical trial.

Zhong Nanshan, one of China’s top respiratory disease experts, said at the conference attended by Yang that he was confident the Chinese vaccines would have good efficacy rates.

When asked about the success of the foreign vaccines, he said: “Pfizer and Moderna have already published their results and the whole world is excited about it, but I am not impressed.”

The US Food and Drug Administration and the World Health Organization demanded an efficacy level of just 50 per cent, he said.

“I don’t care if the efficacy reaches such a high level, like 95 per cent,” Zhong said. “[Our] vaccine is effective and it can be produced on a large scale, and that’s the biggest guarantee.

“I suggest [we] keep an open mind about all types of vaccines as we don’t know how protective the [mRNA] vaccine will be, how long the protection will last and how significant the adverse effects will be in the long run,” he said, referring to the technology used by Pfizer-BioNTech and Moderna.
“With the exception of emergency use authorisation, a vaccine needs at least six months to determine its [true efficacy],” Zhong said.

Nearly 1 million Chinese, including executives of Sinopharm and its subsidiaries, have been given the inactivated vaccines under the government’s emergency use scheme.

Yang, who was among the first to receive an injection, said tests had shown he still had antibodies six months later.

https://www.scmp.com/news/china/science/article/3110690/coronavirus-chinas-cnbg-set-review-covid-19-vaccine-phase-3

@aiyooo *not a joke

@aiyooo I think you need some medications. You are psychotic.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3106655

Lol this aiyoo i think has bipolar disorder. Suddenly come here out of nowhere to personally attack me and when i counter him, he will delete off his comments. Funny fella LOL

@aiyoo If you are on the brink of bankruptcy, just say so, we are happy to help you.

@aiyoo Perhaps you should undergo mental checkup. You need antidepressants and antipsychotics.

@aiyooo is the greatest con man here. So filled with jealousy and hatred. Maybe he lost a lot of money in the market thats why gone cuckoo.

@aiyooo I think you are the insider and the shark lolol So desperate and pathetic, keep coming here to bark.

The global bamboos market size was valued at USD 68.8 billion in 2018 and is expected to grow at a CAGR of 5.0% from 2019 to 2025. Growing investments focused on infrastructure development, increasing use of sustainable building/ construction resources, and rising consumer awareness regarding the uses and benefits of bamboos are expected to drive the market growth over the forecast period.

https://www.grandviewresearch.com/industry-analysis/bamboos-market#:~:text=The%20bamboos%20market%20is%20expected,USD%2098.30%20billion%20by%202027.&text=Asia%20Pacific%20dominated%20the%20bamboos,the%20production%20of%20household%20furniture.

@nik5007 China's economy is already back to normal which means their bamboo product business will start to make profit

----------

Kanger poised to be largest producer of bamboo products

Kanger is on target to become the world’s largest producer of bamboo products with the commencement of a new high-tech bamboo processing plant and R&D centre which was developed in collaboration with the local government of Jingzhou in Hunan Province, China.

With construction of the plant and commissioning of the machinery and equipment now completed, testing works are being carried out, with full commercial production commencing in the fourth quarter of 2020.

https://www.thestar.com.my/business/business-news/2020/09/09/kanger-international-on-track-to-be-largest-producer-of-bamboo-products

@Chua Joe Beng Anything is possible with bamboo company!

EU says 2 Covid-19 vaccines could be approved this year

https://www.freemalaysiatoday.com/category/world/2020/11/20/eu-says-2-covid-19-vaccines-could-be-approved-this-year/